Immunotoxins in the therapy of cancer: From bench to clinic

Victor Ghetie; Ellen Vitetta

doi:10.1016/0163-7258(94)90025-6

Immunotoxins in the therapy of cancer: From bench to clinic

Victor Ghetie, Ellen Vitetta

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

Original language	English (US)
Pages (from-to)	209-234
Number of pages	26
Journal	Pharmacology and Therapeutics
Volume	63
Issue number	3
DOIs	https://doi.org/10.1016/0163-7258(94)90025-6
State	Published - 1994

Keywords

Immunotoxin
cancer
monoclonal antibody
therapy

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/0163-7258(94)90025-6

Cite this

@article{f4de2f507e9840eabdb56098d177ee7d,

title = "Immunotoxins in the therapy of cancer: From bench to clinic",

abstract = "This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.",

keywords = "Immunotoxin, cancer, monoclonal antibody, therapy",

author = "Victor Ghetie and Ellen Vitetta",

year = "1994",

doi = "10.1016/0163-7258(94)90025-6",

language = "English (US)",

volume = "63",

pages = "209--234",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Immunotoxins in the therapy of cancer

T2 - From bench to clinic

AU - Ghetie, Victor

AU - Vitetta, Ellen

PY - 1994

Y1 - 1994

N2 - This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

AB - This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

KW - Immunotoxin

KW - cancer

KW - monoclonal antibody

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=0028062734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028062734&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(94)90025-6

DO - 10.1016/0163-7258(94)90025-6

M3 - Review article

C2 - 7831391

AN - SCOPUS:0028062734

SN - 0163-7258

VL - 63

SP - 209

EP - 234

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

IS - 3

ER -

Immunotoxins in the therapy of cancer: From bench to clinic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this